Found 14 hodgkin lymphoma trials
A listing of hodgkin lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Please refer to Protocol Section 3.1 (Primary Objectives, Endpoints & Hypotheses). Please refer to Protocol Section 3.1 Primary Objectives, Endpoints & Hypotheses. Please refer to Protocol Section 3.2 (Secondary Objectives and Endpoints).
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
Please refer to Protocol 17-054, Section 2.0 (Objectives and Scientific Aims) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Primary Endpoints) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Secondary Endpoints)
Assess magnitude of the baseline differences between participants with early Huntington's Disease & healthy participants with respect to measures of cognitive performance, evaluate effect of SAGE-718 on cognition & functioning outcomes in participants with HD & to evaluate safety & tolerability of SAGE718 in participants with HD, evaluate reliability & …
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: can a safe dose of JNJ-90009530 be determined that is safe and well tolerated by patients. will JNJ-90009530 help patients achieve a response and …
Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints).
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
1 - 10 of 14
- 1
- 2
